Can a smartphone app reduce emergency department revisits for asthma

Asthma can change quickly. A person may feel better after emergency treatment, yet remain vulnerable to another flare-up when they return home. Medication confusion, ongoing exposure to triggers, delayed follow-up and difficulty recognising worsening symptoms can all contribute to an unplanned return to the emergency department.

A smartphone app may help close some of these gaps. It can provide reminders, symptom tracking, inhaler education and links to clinical support between visits. However, digital access alone does not guarantee safer care. The app must be clinically appropriate, easy to use and connected to an asthma management plan developed with health professionals.

For a health translation network such as Brisbane Diamantina Health Partners, the important question is less about whether an app is fashionable and more about whether it improves measurable outcomes for patients, families, carers and communities. That requires research, co-design and careful evaluation in real-world Queensland settings.

Why people return to hospital after an asthma attack

Emergency treatment often focuses on stabilising breathing, relieving bronchoconstriction and ruling out immediate danger. Once symptoms settle, patients may still need a clear written action plan, a medication review, inhaler technique coaching and timely primary care follow-up. If any of these steps are missed, the underlying risk may remain.

Some revisits occur because people cannot obtain prescriptions, misunderstand preventer and reliever medicines, or stop treatment as soon as they feel better. Others may face poor housing conditions, smoke exposure, transport barriers, limited health literacy or difficulty accessing a general practitioner. These social and clinical factors mean an app should support a broader care pathway rather than act as a standalone solution.

How a digital asthma tool could help

A well-designed application could send personalised reminders for preventer medication, record symptoms and prompt users to check peak expiratory flow when appropriate. Simple questions about night waking, wheeze, breathlessness and reliever use could identify deterioration earlier, especially when linked to agreed escalation advice.

The tool might also display an individual asthma action plan in plain language, include short inhaler technique videos and prepare users for a follow-up appointment. Notifications could remind people to schedule a review after discharge, while secure messaging could help a clinical team decide whether a phone call or face-to-face assessment is needed.

That does not mean every alert should trigger an emergency response. Poorly calibrated notifications may cause anxiety, alert fatigue or unnecessary health service use. Clinical governance must define who reviews data, how quickly they respond and what happens when a user reports severe symptoms.

What researchers need to measure

The central outcome is a reduction in emergency department revisits within a defined period, such as 30 or 90 days. Researchers should also examine hospital admissions, ambulance use, oral corticosteroid courses, symptom control and quality of life. A lower revisit rate is meaningful only if patients remain safe and receive appropriate care.

A robust evaluation could compare app-supported discharge with usual care through a randomised trial or a carefully designed implementation study. Researchers should record how often people use the application, which features they access and whether engagement changes over time. Patient-reported outcomes can reveal benefits or harms that administrative data may miss.

Translation into practice also depends on understanding how evidence moves between laboratories, clinics and communities. For example, the work of a researcher Dr Jane Smith illustrates how disease-focused research can connect with better patient outcomes. Asthma technology should be assessed with the same attention to clinical relevance, implementation and equity.

Comparing possible care pathways

An app is best judged against the alternatives available after emergency discharge, not against an idealised model of care. Usual care may be effective when it includes timely follow-up and education, while digital support may add value where communication gaps are common. The strongest approach may combine technology with nurse-led or general practice review.

A partnership model can help determine which option fits different populations. The Mater translational program demonstrates the value of connecting research expertise with health service delivery. For asthma, this could involve emergency clinicians, respiratory specialists, pharmacists, primary care teams, software designers and people living with asthma.

Making the app useful for diverse communities

Digital health interventions should be co-designed with people who use emergency services, including adolescents, older adults, parents of children with asthma and people living in rural or outer metropolitan areas. The design should support accessibility features, low digital literacy and different language needs. It should also work reliably on older devices and use minimal data where connectivity is limited.

Privacy and safety require explicit attention. Health information should be encrypted, access should be controlled and users should understand what is collected and who can see it. An app must state clearly that severe breathing difficulty, blue lips, collapse or inability to speak normally requires urgent emergency care rather than waiting for a notification or clinician reply.

Personalisation can improve relevance. A user exposed to occupational dust may need different prompts from a child whose symptoms are linked to viral infections or a person affected by tobacco smoke. Research into biological variation can also inform broader respiratory care; discussions of epigenetics and lung cancer show why environmental exposure and individual susceptibility deserve careful scientific attention, even though asthma and cancer are distinct conditions.

Building an evaluation into clinical practice

Before adoption, health services should define the clinical problem, target population and intended mechanism of benefit. A tool designed for people discharged after an acute asthma episode may need different functions from one used for long-term disease management. Ethics approval, information governance, interoperability and staff training should be addressed from the beginning.

The implementation plan should include a route for technical support and a process for reviewing adverse events. It should also assess whether the app reaches people who are most likely to revisit hospital, rather than mainly attracting confident users with stable disease. Cost, staff workload and the consequences of digital exclusion belong in the evaluation alongside clinical outcomes.

Practical priorities for health services

• Co-design the app with patients, carers, clinicians and communities affected by asthma.
• Link symptom prompts to a personalised action plan and clear emergency advice.
• Provide human follow-up through primary care, pharmacy, nursing or respiratory services.
• Measure revisits, admissions, safety events, equity, engagement and cost over time.
• Test the intervention in routine Queensland settings before scaling it across services.

A smartphone app could reduce emergency department revisits for some people with asthma, particularly when it reinforces medication use, recognises deterioration and connects patients with timely professional support. Its value should be demonstrated through transparent, patient-centred research rather than assumed from download numbers. Health services, researchers and communities can work together to test the model, publish the findings and translate effective digital care into safer asthma management.